At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed recurrent or metastatic ovarian epithelial cancer or primary peritoneal cancer
- ✓Unidimensionally measurable disease (previously irradiated lesions must show progression post-radiotherapy)
- ✓Prior platinum-containing regimen for primary disease required
- ✓No more than 2 prior chemotherapy regimens for recurrent disease; platinum rechallenge counted as 1 regimen
- ✕Brain metastases or CNS disease including primary brain tumor
- ✕Prior deep vein thrombosis, stroke, or clinically significant cardiovascular disease
- ✕Within past year: uncontrolled hypertension, NYHA class II-IV heart failure, serious cardiac arrhythmia, or grade II+ peripheral vascular disease
- ✕Within past 6 months: unstable angina, myocardial infarction, TIA, stroke, or arterial thromboembolic event
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial of Bevacizumab (NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Cyclophosphamide, and 1 other intervention for Primary Peritoneal Carcinoma and 2 related conditions. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This phase II trial is to see if combining bevacizumab with low-dose cyclophosphamide works in treating patients with ovarian epithelial or primary peritoneal cancer that has come back or spread to other parts of the body. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining bevacizumab with cyclophosphamide may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given PO
Correlative studies